InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-21 | 2025-05-22 | Jasinski Lawrence J | Director & Chief Executive Officer | Sale | 1,909 | $1.26 | $2K | 98.7K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $22.0M-14.1% | $25.7M+85.2% | $13.9M+151.4% | $5.5M-7.6% | $6.0M |
| Cost of revenue | $13.6M-22.0% | $17.4M+85.6% | $9.4M+160.7% | $3.6M+17.7% | $3.1M |
| Gross profit | $8.4M+2.6% | $8.2M+84.5% | $4.5M+133.8% | $1.9M-34.4% | $2.9M |
| Research and development, net | $3.2M-29.8% | $4.6M+11.5% | $4.1M+2.9% | $4.0M+37.2% | $2.9M |
| Sales and marketing | $13.9M-22.7% | $17.9M+28.9% | $13.9M+41.5% | $9.8M+40.7% | $7.0M |
| General and administrative | $8.2M+57.7% | $5.2M-48.0% | $10.0M+40.1% | $7.1M+26.8% | $5.6M |
| Impairment charges | $2.8M-71.6% | $9.8M | $0 | $0 | — |
| Total operating expenses | $28.1M-25.2% | $37.6M+33.8% | $28.1M+33.6% | $21.0M+35.0% | $15.6M |
| Operating loss | -$19.7M+33.0% | -$29.3M-24.3% | -$23.6M-23.6% | -$19.1M-50.9% | -$12.7M |
| Financial (expense) income, net | -$295K-165.8% | $448K-69.5% | $1.5M | — | — |
| Loss before income taxes | -$20.0M+30.9% | -$28.9M-30.5% | -$22.1M-15.9% | -$19.1M-51.1% | -$12.6M |
| Taxes on income (benefit) | -$55K-227.9% | $43K+458.3% | -$12K-102.6% | $467K+396.8% | $94K |
| Net loss | -$19.9M+31.2% | -$28.9M-30.8% | -$22.1M-13.1% | -$19.6M-53.7% | -$12.7M |
| Net loss per ordinary share, basic | -$17K+57.1% | -$40K-28.4% | -$31K-1315.0% | -$2K-714.8% | -$270 |
| Net loss per ordinary share, diluted | -$17K+57.1% | -$40K-28.4% | -$31K-1315.0% | -$2K-714.8% | -$270 |
| Weighted average number of shares used in computing net loss per ordinary share, basic | $1.16B+60.2% | $724.3M+1.9% | $710.9M-92.0% | $8.91B-81.4% | $47.94B |
| Weighted average number of shares used in computing net loss per ordinary share, diluted | $1.16B+60.2% | $724.3M+1.9% | $710.9M-92.0% | $8.91B-81.4% | $47.94B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Oramed Pharmaceuticals: 'Hold' On Oral Insulin Drug Failure Pivot And New Strategic Investment Direction
Lifeward Appoints Dr. Keith D. Rose as Chief Medical Officer to Support Expansion of Neurorehabilitation Portfolio and Advance Biomed Platform
How The Lifeward (LFWD) Story Is Shifting With New Price Targets And Valuation Assumptions
Lifeward Ltd (LFWD) Q1 2026 Earnings Call Highlights: Navigating Challenges and Seizing Growth ...